Google
Trusted Resources: Evidence & Education
Scientific literature and patient education texts
Access to Care, and Emergency Department Utilization for Adults and Adolescents With Sickle Cell Disease: Ascq-Me and the SHIP-HU Study
source: American Society of Hematology
year: 2017
authors: Wally R. Smith, Donna k McClish, Richard Lottenberg, India Sisler, Thokozeni Lipato, Ian Chen, Shirley Johnson, Ding-Yu Fei, Daniel Sop Mouaffo
summary/abstract:Measurement of access to care and utilization for adults with sickle cell disease (SCD) compared to children has been primarily through analysis of administrative databases. We report here the first comparative results of the Adult Sickle Cell Quality of Life Measurement Information System (ASCQ-Me) access and utilization measures for adolescents vs. adults.
Methods: Patients (N=186, 55% female) ages 15 and older were enrolled in the Start Healing in Patients with Hydroxyurea (SHIP-HU) clinical trial, which required them to see a SCD specialist. Patients were either seen in 3 adult-oriented clinic sites, or seen in 3 pediatric-oriented clinic sites. At baseline, ASCQ-Me queried care seeking and numbers of visits for both ambulatory and Emergency Department (ED) care.
Results: Fully 92% had a usual care doctor or nurse, their SCD provider, whom they saw on average 3.3 times in the previous 12 months (p=0.7074, patients seen in adult-oriented clinics [A-Cl] vs. patients seen in pediatric-oriented clinics [P-Cl]).^ At baseline, 77.7% of A-Cl and 89.4% of P-Cl were on HU (p=0.0769). In the past 12 months, 87% of A-Cl vs. 73% of P-Cl had tried to make an appointment to see a doctor or nurse (p=0.0321). Compared to all other responses (never, sometimes, usually), only 36% of A-Cl vs. 49% of P-Cl said they could always get an appointment soon enough (p=0.1967). A total of 64/135 A-Cl (47%) vs. 10/47 P-Cl (21%) reported no crises in the preceding 12 months (p=0.0017). Among those reporting home-managed crises without medical contact, the mean number was 2.0 for A-Cl vs 2.7 for P-Cl (p=0.0241). ^ Fully 66% of A-Cl vs. 43% of P-Cl at some point delayed/ avoided ED care for crises (p=0.0039). Reasons for avoiding ED care included prior bad experiences (very, quite, or somewhat important for 63% of A-Cl vs. 45% of P-Cl, p=0.1458) and health insurance issues (very, quite, or somewhat important for 30% of A-Cl vs. 40% of P-Cl, p=0.3680). Still, 76% of A-Cl vs 54% of P-Cl reported ED visits for crises (p=0.0043). The mean number of ED visits was 2.2 for A-Cl vs. 1.2 for P-Cl (p=0.0003).^ Compared to all other responses (never, sometimes, usually), only 19% of A-Cl vs. 38% of P-Cl said they could always get ED care as soon as they wanted (p=0.0540)–49% of A-Cl vs. 16% of P-Cl had to wait more than an hour to be medicated in the ED (p=0.0031; 32% of A-Cl vs 8% of P-Cl had to wait more than 2 hours (p=0.0156).
organization: Virginia Commonwealth University, Richmond, VAread more
+myBinderRelated Content
-
Jon Mark Hirshon, MDJon Mark Hirshon, MD, PhD, MPH, FACEP, F...
-
Chavis Patterson, PhDDr. Chavis Patterson is a licensed Clini...
-
Sickle cell patients in UK survey, especially those 16 to 20, voice problems with care and pain relief givenIn a survey, patients across the...
-
Duke University Comprehensive Sickle Cell CenterHematologists at the Duke University Com...
-
My medical school lesson was tinged with racism. Did that affect how I treated a sickle cell patient years later?The young woman was curled up in a ball....
-
Today’s Faces of Sickle Cell Disease: Carolyn Rowley, PhDCarolyn Rowley is a psychologist, patien...
-
Teens with Sickle Cell Disease Moving from Pediatric Care to Adult CareMoving from pediatric (children’s) car...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.